Lentiviral-mediated delivery of classical swine fever virus Erns gene into porcine kidney-15 cells for production of recombinant ELISA diagnostic antigen

Bhattacharya, Supriya; Saini, Mohini; Bisht, Deepika; Rana, Mashidur; Bachan, Ram; Gogoi, Sailen; Buragohain, Bijoy M; Barman, Nagendra Nath; Gupta, Praveen Kumar

doi:10.1007/s11033-019-04829-0

“…Over the past 30 years, many methods have been proposed to deliver exogenous genes and cells to target organs [31,38,45,95,98,100,128,140,[147][148][149][150][151][152][153][154][155]. From a fundamental viewpoint, these techniques seek to provide inexpensive and rapid alternatives to pronuclear microinjection-derived transgenic models and platforms for translational studies [119].…”

Section: The Development Of Efficient Delivery Techniquesmentioning

confidence: 99%

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Corridon¹

2023

Preprint

View full text Add to dashboard Cite

The rising global incidence of acute and chronic kidney diseases has increased the demand for renal replacement therapy. This issue, compounded with the limited availability of viable kidneys for transplantation, has propelled the search for alternative strategies to address the growing health and economic burdens associated with these conditions. In the search for such alternatives, significant efforts have been devised to augment the current and primarily supportive management of renal injury with novel regenerative strategies. For example, gene- and cell-based approaches that utilize recombinant peptides/proteins, gene, cell, organoid, and RNAi technologies have shown promising outcomes primarily in experimental models. Supporting research has also been conducted to improve our understanding of the critical aspects that facilitate the development of efficient gene- and cell-based techniques that the complex structure of the kidney has traditionally limited. This manuscript is intended to communicate efforts that have driven the development of such therapies by identifying the vectors and delivery routes needed to drive exogenous transgene incorporation that may support the treatment of acute and chronic kidney diseases.

show abstract

“…Over the past 30 years, many methods have been proposed to deliver exogenous genes and cells to target organs (32,39,46,97,100,102,130,142,(149)(150)(151)(152)(153)(154)(155)(156)(157). From a fundamental viewpoint, these techniques seek to provide inexpensive and rapid alternatives to pronuclear microinjection-derived transgenic models and platforms for translational studies (121).…”

Section: Key Aspects To Facilitate Advancements In Renal Genetic Medi...mentioning

confidence: 99%

Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles

Corridon

¹

2023

View full text Add to dashboard Cite

The rising global incidence of acute and chronic kidney diseases has increased the demand for renal replacement therapy. This issue, compounded with the limited availability of viable kidneys for transplantation, has propelled the search for alternative strategies to address the growing health and economic burdens associated with these conditions. In the search for such alternatives, significant efforts have been devised to augment the current and primarily supportive management of renal injury with novel regenerative strategies. For example, gene- and cell-based approaches that utilize recombinant peptides/proteins, gene, cell, organoid, and RNAi technologies have shown promising outcomes primarily in experimental models. Supporting research has also been conducted to improve our understanding of the critical aspects that facilitate the development of efficient gene- and cell-based techniques that the complex structure of the kidney has traditionally limited. This manuscript is intended to communicate efforts that have driven the development of such therapies by identifying the vectors and delivery routes needed to drive exogenous transgene incorporation that may support the treatment of acute and chronic kidney diseases.

show abstract

“…The lentiviral packaging cell line 293LTV is a transformed cell line derived from the human primary embryonic kidney cell line 293 and is frequently used to produce lentiviral particles (23,24). To achieve the expression of fluorescent BORIS sf2-EGFP fusion proteins, we cloned the cDNA containing the BORIS sf2 gene sequence into the NheI and AgeI sites of the plasmid pCS-CG (Figure 1A).…”

Section: A Failed Establishment Of Stable Cell Lines Expressing Boris...mentioning

confidence: 99%

Establishment and evaluation of cell and animal models expressing BORIS subfamily 2 variant

Qin¹,

Liu²,

Xian³

et al. 2022

Ann Transl Med

1

0

View full text Add to dashboard Cite

Background: The possibility of a cancer vaccine aimed at stimulating or mobilizing the body's immune system to control and kill tumor cells is emerging as a potential new strategy for tumor immunological therapy. CCCTC-binding Factor Like (CTCFL)/Brother of the Regulator of Imprinted Sites (BORIS), a cancer-testis antigen (CTA), has 23 mRNA splice variants classified into six subfamilies (sfs) and potentially encodes 17 distinct polypeptides. Based on our previous long-term research on hepatocellular carcinoma (HCC), we were particularly interested in whether BORIS sf2 could be a promising candidate for immunotherapy targeting liver cancer cells. Therefore, in this study, we aimed to construct an animal model to study the immunogenicity of human BORIS sf2 in murine hepatoma cells. Methods:We established a hepatoma cell line expressing human BORIS sf2/C68 by inserting the sequences into a lentiviral vector pLVX-EF1α-IRES-Puro carrying the puromycin resistance gene. We achieved the stabilized expression of BORIS sf2/C68 in the oncogenic Hepa1c1c7 cells through lentivirusmediated approach. The Hepa1c1c7 cells expressing the BORIS sf2/C68 (5×10 6 /mouse) were inoculated subcutaneously into 6-week-old C57BL/6 mice to induce the formation of tumors. Results:In the tumor formation experiment, the murine hepatoma cells expressing human BORIS sf2/C68 showed progressive growth in C57BL/6 mice. The animal model we constructed could be used to study the in vivo immunogenicity of the human BORIS sf2 in murine hepatoma cells. Conclusions:The animals bearing BORIS sf2/C68-positive tumors may serve as an animal model for studying the therapeutic potency and safety of HCC vaccine directed at the CT-antigen BORIS sf2.

show abstract

Lentiviral-mediated delivery of classical swine fever virus Erns gene into porcine kidney-15 cells for production of recombinant ELISA diagnostic antigen

Cited by 5 publications

References 47 publications

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Still Finding Ways to Augment the Existing Management of Acute and Chronic Kidney Diseases with Targeted Gene and Cell Therapies: Opportunities and Hurdles

Still finding ways to augment the existing management of acute and chronic kidney diseases with targeted gene and cell therapies: Opportunities and hurdles

Establishment and evaluation of cell and animal models expressing BORIS subfamily 2 variant

Contact Info

Product

Resources

About